AU2016275125A1 - Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid - Google Patents

Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid Download PDF

Info

Publication number
AU2016275125A1
AU2016275125A1 AU2016275125A AU2016275125A AU2016275125A1 AU 2016275125 A1 AU2016275125 A1 AU 2016275125A1 AU 2016275125 A AU2016275125 A AU 2016275125A AU 2016275125 A AU2016275125 A AU 2016275125A AU 2016275125 A1 AU2016275125 A1 AU 2016275125A1
Authority
AU
Australia
Prior art keywords
crystalline form
xrpd
lai
diffractometer
radiation
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Abandoned
Application number
AU2016275125A
Other languages
English (en)
Inventor
Antonio J. Barbosa
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
GB006 Inc
Original Assignee
GB006 Inc
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by GB006 Inc filed Critical GB006 Inc
Publication of AU2016275125A1 publication Critical patent/AU2016275125A1/en
Assigned to GB006, INC. reassignment GB006, INC. Request for Assignment Assignors: ADHAERE PHARMACEUTICALS, INC.
Priority to AU2020270457A priority Critical patent/AU2020270457B2/en
Abandoned legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D417/00—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00
    • C07D417/02—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings
    • C07D417/06—Heterocyclic compounds containing two or more hetero rings, at least one ring having nitrogen and sulfur atoms as the only ring hetero atoms, not provided for by group C07D415/00 containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/41—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having five-membered rings with two or more ring hetero atoms, at least one of which being nitrogen, e.g. tetrazole
    • A61K31/425—Thiazoles
    • A61K31/427—Thiazoles not condensed and containing further heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00—Antineoplastic agents
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/08—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with only one hydroxy group and one amino group bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/04—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated
    • C07C215/06—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic
    • C07C215/10—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton the carbon skeleton being saturated and acyclic with one amino group and at least two hydroxy groups bound to the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07C—ACYCLIC OR CARBOCYCLIC COMPOUNDS
    • C07C215/00—Compounds containing amino and hydroxy groups bound to the same carbon skeleton
    • C07C215/02—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton
    • C07C215/40—Compounds containing amino and hydroxy groups bound to the same carbon skeleton having hydroxy groups and amino groups bound to acyclic carbon atoms of the same carbon skeleton with quaternised nitrogen atoms bound to carbon atoms of the carbon skeleton
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07B—GENERAL METHODS OF ORGANIC CHEMISTRY; APPARATUS THEREFOR
    • C07B2200/00—Indexing scheme relating to specific properties of organic compounds
    • C07B2200/13—Crystalline forms, e.g. polymorphs

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Medicinal Chemistry (AREA)
  • Public Health (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Epidemiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
AU2016275125A 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid Abandoned AU2016275125A1 (en)

Priority Applications (1)

Application Number Priority Date Filing Date Title
AU2020270457A AU2020270457B2 (en) 2015-06-12 2020-11-16 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Applications Claiming Priority (5)

Application Number Priority Date Filing Date Title
US201562175066P 2015-06-12 2015-06-12
US62/175,066 2015-06-12
US201662275655P 2016-01-06 2016-01-06
US62/275,655 2016-01-06
PCT/US2016/037067 WO2016201356A1 (en) 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Related Child Applications (1)

Application Number Title Priority Date Filing Date
AU2020270457A Division AU2020270457B2 (en) 2015-06-12 2020-11-16 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Publications (1)

Publication Number Publication Date
AU2016275125A1 true AU2016275125A1 (en) 2018-01-25

Family

ID=57504544

Family Applications (2)

Application Number Title Priority Date Filing Date
AU2016275125A Abandoned AU2016275125A1 (en) 2015-06-12 2016-06-10 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
AU2020270457A Active AU2020270457B2 (en) 2015-06-12 2020-11-16 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Family Applications After (1)

Application Number Title Priority Date Filing Date
AU2020270457A Active AU2020270457B2 (en) 2015-06-12 2020-11-16 Solid forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid

Country Status (12)

Country Link
US (4) US10723726B2 (enExample)
EP (1) EP3307722B1 (enExample)
JP (1) JP2018521121A (enExample)
KR (1) KR102663856B1 (enExample)
CN (1) CN107848991B (enExample)
AU (2) AU2016275125A1 (enExample)
BR (2) BR112017026406A2 (enExample)
CA (2) CA3221219A1 (enExample)
ES (1) ES2896674T3 (enExample)
IL (1) IL256237B (enExample)
SG (1) SG10201911442XA (enExample)
WO (1) WO2016201356A1 (enExample)

Families Citing this family (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
BR112017026406A2 (pt) 2015-06-12 2019-04-02 Adhaere Pharmaceuticals, Inc. formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico
WO2018126072A1 (en) * 2016-12-29 2018-07-05 Adhaere Pharmaceuticals, Inc. Heterocyclic integrin agonists
IL269667B2 (en) * 2017-03-30 2024-09-01 Merck Patent GmbH Solid forms of (s)-[2-chloro-4-fluoro-5-(7-morpholin-4-ylquinazolin-4-yl)phenyl]-(6-methoxy-pyridazin-3-yl) methanol, its preparation and pharmaceutical compositions containing them
TWI687415B (zh) 2017-08-17 2020-03-11 美商基利科學股份有限公司 Hiv蛋白質膜抑制劑之固體形式
KR102858291B1 (ko) * 2018-11-28 2025-09-12 뤄신 파마슈티컬 (상하이) 컴퍼니 리미티드 에스트로겐 수용체 하향 조절제의 염 형태와 결정형, 및 이의 제조방법
WO2020236667A1 (en) 2019-05-17 2020-11-26 Gb006, Inc. Methods of treating cancer
WO2021061665A1 (en) * 2019-09-23 2021-04-01 Gb006, Inc. Integrin agonist prodrugs
WO2021096988A1 (en) 2019-11-12 2021-05-20 Gb006, Inc. Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
WO2023039170A1 (en) * 2021-09-09 2023-03-16 Musc Foundation For Research Development Selective targeting of cd38 activity as an immunostimulatory and antitumor strategy
JP2025529972A (ja) * 2022-09-02 2025-09-09 レックスファームテック カンパニー リミテッド 新規ベンフォチアミンコリン塩
WO2024081449A1 (en) * 2022-10-14 2024-04-18 Rush University Medical Center Cd11b agonists for treatment of autoimmune disease

Family Cites Families (13)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20040002526A1 (en) * 2002-04-03 2004-01-01 Cell Therapeutics, Inc. Phospholipase D inhibitors and uses thereof
EP1654380A4 (en) 2003-08-14 2009-09-09 Insight Biopharmaceuticals Ltd METHODS AND PHARMACEUTICAL COMPOSITIONS FOR MODULATING HEPARANASE ACTIVATION AND USES THEREOF
TW200526638A (en) * 2003-10-22 2005-08-16 Smithkline Beecham Corp 2-(3,4-dimethylphenyl)-4-{[2-hydroxy-3'-(1H-tetrazol-5-yl)biphenyl-3-yl]-hydrazono}-5-methyl-2,4-dihydropyrazol-3-one choline
FI20041129A0 (fi) 2004-08-30 2004-08-30 Ctt Cancer Targeting Tech Oy Tioksotiatsolidinoniyhdisteitä lääkkeinä käytettäviksi
US7718680B2 (en) * 2004-09-23 2010-05-18 Burnham Institute For Medical Research Inhibition of lethal factor protease activity from anthrax toxin
ITMI20042475A1 (it) * 2004-12-23 2005-03-23 Cell Therapeutics Europe Srl Uso di derivati tiazolidinonici come agenti terapeutici
WO2008005651A2 (en) * 2006-06-08 2008-01-10 Decode Chemistry, Inc. Cyclic carboxylic acid rhodanine derivatives for the treatment and prevention of tuberculosis
WO2008082537A2 (en) 2006-12-19 2008-07-10 The General Hospital Corporation Compounds for modulating integrin cd11b/cd18
WO2008091532A1 (en) * 2007-01-19 2008-07-31 Panacos Pharmaceuticals, Inc. Salts of 3-o-(3',3'-dimethylsuccinyl)betulinic acid and solid state forms thereof
US9023876B2 (en) 2010-07-08 2015-05-05 Adhaere Pharmaceuticals, Inc. Compounds and methods for regulating integrins
CN103159695B (zh) * 2011-12-08 2015-08-12 首都师范大学 可抑制hiv复制并对耐药hiv病毒株有效的噻唑类化合物及其制备方法和用途
EP2838614B1 (en) 2012-04-20 2019-09-11 GB006, Inc. Compositions for regulating integrins
BR112017026406A2 (pt) 2015-06-12 2019-04-02 Adhaere Pharmaceuticals, Inc. formas sólidas de ácido (z)-4-(5-((3-benzil-4-oxo-2-tioxotiazolidin-5-ilideno)metil)furan-2-il)benzoico

Also Published As

Publication number Publication date
KR20180016443A (ko) 2018-02-14
US20230227443A1 (en) 2023-07-20
EP3307722A4 (en) 2018-12-05
EP3307722B1 (en) 2021-08-04
AU2020270457A1 (en) 2020-12-10
CA2988584C (en) 2024-01-23
JP2018521121A (ja) 2018-08-02
CA3221219A1 (en) 2016-12-15
NZ738836A (en) 2024-03-22
US12227497B2 (en) 2025-02-18
US20180354938A1 (en) 2018-12-13
EP3307722A1 (en) 2018-04-18
US11111239B2 (en) 2021-09-07
IL256237A (en) 2018-02-28
BR122023025347A2 (pt) 2024-01-16
US20250353840A1 (en) 2025-11-20
IL256237B (en) 2021-12-01
US20200317657A1 (en) 2020-10-08
US10723726B2 (en) 2020-07-28
CA2988584A1 (en) 2016-12-15
SG10201911442XA (en) 2020-02-27
CN107848991B (zh) 2022-01-14
AU2020270457B2 (en) 2022-10-20
ES2896674T3 (es) 2022-02-25
WO2016201356A1 (en) 2016-12-15
CN107848991A (zh) 2018-03-27
KR102663856B1 (ko) 2024-05-07
BR112017026406A2 (pt) 2019-04-02

Similar Documents

Publication Publication Date Title
US12227497B2 (en) Solid forms of(Z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
US20250002481A1 (en) 6-pyrimidin-isoindole derivative as erk1/2 inhibitor
KR102241258B1 (ko) 암을 치료하기 위한 1-테트라히드로피라닐카르보닐-2,3-디히드로-1h-인돌 화합물
JP2024521473A (ja) 抗がん剤として有用な縮合ヘテロアリール化合物
JP2023540270A (ja) 複素環式化合物およびその使用
KR101578309B1 (ko) 노치 경로 신호전달 억제제 화합물
JP2022186995A (ja) 固体形態のｃｄｋ４阻害薬
KR20180058741A (ko) 이소퀴놀리논의 고체형, 그의 제조 방법, 이를 포함하는 조성물 및 이를 사용하는 방법
JP2024537795A (ja) ヘテロ芳香族大環状エーテル化合物の固体形態、薬学的組成物、及び調製
CN111093651A (zh) Ido抑制剂的无定形和结晶形式
KR20230124648A (ko) Eif4e 억제제의 고체 형태
US11124519B2 (en) Cocrystal forms of ((1S,2S,4R)-4-{4-[(1S)-2,3-dihydro-1H-inden-1-ylamino]-7H-pyrrolo [2,3-d]pyrimidin-7-yl}-2-hydroxycyclopentyl) methyl sulfamate, formulations and uses thereof
EP3242661A1 (en) Myc g-quadruplex stabilizing small molecules and their use
JP2025525376A (ja) 医学的治療用のサイクリン依存性キナーゼ２阻害剤
TW201833099A (zh) 喹啉衍生物的乙磺酸鹽
WO2021096988A1 (en) Crystalline salt forms of (z)-4-(5-((3-benzyl-4-oxo-2-thioxothiazolidin-5-ylidene)methyl)furan-2-yl)benzoic acid
RU2786994C2 (ru) Фармацевтическое соединение
CA3009355C (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide
US9718824B2 (en) Solid forms comprising 7-(6-(2-hydroxypropan-2-yl)pyridin-3-yl)-1-((trans)-4-methoxycyclohexyl)-3,4-dihydropyrazino[2,3-b]pyrazin-2(1H)-one, and a coformer, compositions and methods of use thereof
CA3009355A1 (en) Salt forms and polymorphs of (r)-1-(4-(6-(2-(4-(3,3-difluorocyclobutoxy)-6-methylpyridin-2-yl) acetamido) pyridazin-3-yl)-2-fluorobutyl)-n-methyl-1h-1,2,3-triazole-4-carboxamide

Legal Events

Date Code Title Description
PC1 Assignment before grant (sect. 113)

Owner name: GB006, INC.

Free format text: FORMER APPLICANT(S): ADHAERE PHARMACEUTICALS, INC.

MK5 Application lapsed section 142(2)(e) - patent request and compl. specification not accepted